You can buy or sell Zymeworks and other stocks, options, ETFs, and crypto commission-free!
Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
Vancouver, British Columbia
52 Week High
52 Week Low
Financial PostMay 23
Zymeworks Announces Corporate Update Conference Call
VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will host a webcast and conference call to discuss progress on its 2019 corporate priorities, including clinical development plans for its lead therapeutic candidates as well as recently announced and established corporate partnerships. Zymeworks will host a webcast and conference call on Wednesday, May 29, 2019 at 8:30am ET (5:30am PT...
Seeking AlphaMay 16
GSK expands collaboration with Zymeworks
GlaxoSmithKline (NYSE:GSK) has expanded the scope of its 2016 licensing and collaboration partnership with Zymeworks (NYSE:ZYME), now enabling access to the latter's heavy-light chain pairing technology which is part of its Azymetric platform.
Expected Jul 31, After Hours